

Oxurion ontvangt aangepaste transparantiekennisgevingen van Atlas Special Opportunities II LLC

Leuven, BELGIË – 12 juni 2025 – 18u00 CET [Oxurion NV](#) (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving¹, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 11 juni 2025 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 3 juni 2025 2.340.268 aandelen van de toen uitstaande 8.496.303 aandelen bezat en dus boven de drempel (25%) kwam door de aankoop van stemrechtverlenende effecten.

Oxurion ontving een transparantiekennisgeving op 9 juni 2025 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 6 juni 2025 2.061.174 aandelen van de toen uitstaande 8.496.303 aandelen bezat en dus onder de drempel (25%) kwam door de verkoop van stemrechtverlenende effecten.

Dit persbericht vervangt het persbericht gepubliceerd op 11 juni 2025.

Over Oxurion

Oxurion NV (Euronext Brussel: OXUR) is een biofarmaceutische groep in transitie, die therapeutische innovatie combineert met technologieën toegepast op klinisch onderzoek. Via zijn snelgroeiende technologische tak ontwikkelt Oxurion geïntegreerde expertise rond klinische data, met als ambitie om de ontwikkelingsprocessen van nieuwe behandelingen te versnellen, te beveiligen en te transformeren. Het hoofdkantoor van de groep is gevestigd in Leuven, België. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Voor meer informatie kunt u contact opnemen met:

<p>Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com</p>
--

1. Art 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name: OKURION
 Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights +

4) Notification by

A person that notifies alone +

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

03/06/2025 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

25

i If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

8,496,303

i Please enter the denominator before filling in the data


10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	244,798	2,340,268		27.33%	
TOTAL		2,340,268	0	27.54%	0.00%

+

i Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
 For groups, start with the ultimate controlling natural person or legal entity.
 The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial Instruments	After the transaction						
	Holder of equivalent financial Instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL					0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	2,340,268	27.54%

CALCULATE

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of (DD/MM/YYYY)


13) Additional information

On 26 May 2025 (with settlement date on 30 May 2025), Atlas Special Opportunities II LLC sold 307,241 shares in Oxurion NV, as a result of which its shareholding decreased to 244,796 shares (= 3.96%, denominator = 6,156,035).
 On 2 June 2025 (with settlement date on 3 June 2025), Atlas Special Opportunities II LLC acquired 2,340,268 shares in Oxurion NV, as a result of which its shareholding increased to 2,340,268 shares (= 27.54%, denominator = 8,496,303).

Done at

On (DD/MM/YYYY)

Name & capacity

Signature 

For security reasons, the unsigned form in **xlsx** format should be transmitted to trp.fin@fsm.a.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.

ANNEX 2

FSMA <small>FINANCIAL SERVICES AND MARKETS AUTHORITY</small>	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name: OXURION
 Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

06/06/2025 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

25

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

8,496,303

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	2,340,268	2,061,174	0	24.26%	0.00%
TOTAL		2,061,174	0	24.26%	0.00%

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	2,061,174 24.26%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of (DD/MM/YYYY)

13) Additional information

On 28 May 2025 (with settlement date on 30 May 2025), Atlas Special Opportunities II LLC sold 307,241 shares in Oxurion NV, as a result of which its shareholding decreased to 244,798 shares (= 3.98%, denominator = 6,156,035).
 On 2 June 2025 (with settlement date on 4 June 2025), Atlas Special Opportunities II LLC acquired 2,340,268 shares in Oxurion NV, as a result of which its shareholding increased to 2,340,268 shares (= 27.54%, denominator = 8,496,303).
 On 4 June 2025 (with settlement date on 6 June 2025), Atlas Special Opportunities II LLC sold 243,534 shares in Oxurion NV, as a result of which its shareholding decreased to 2,061,174 shares (= 24.26%, denominator = 8,496,303).

Done at New York
 On 06/06/2025 (DD/MM/YYYY)
 Name & capacity Patrick Vance, Proxyholder

Signature Signed-by:
Patrick Vance
 9A8C4789B05442E...

For security reasons, the unsigned form in xlsx format should be transmitted to trp.fin@fsm.a.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.
 In addition, a signed copy in PDF format should also be transmitted.